08:10 AM EDT, 05/09/2024 (MT Newswires) -- Royalty Pharma ( RPRX ) reported Thursday Q1 net income attributable to the company of $5 million, down from $341 million a year earlier.

Analysts' estimates were not readily available for comparison.

Total income and other revenue for the quarter ended March 31 were $568 million, down from $684 million a year earlier.

Three analysts surveyed by Capital IQ expected $709.5 million.

As of the quarter end, the company said it had $843 million in cash and cash equivalents.

Price: 28.00, Change: +0.01, Percent Change: +0.04